Biran, N.Jacobus, S.Vesole, D. H.Callander, N. S.Fonseca, R.Williams, M. E.Abonour, R.Katz, M. S.Rajkumar, S. V.Greipp, P. R.Siegel, D. S.2016-12-152016-12-152016-09Biran, N., Jacobus, S., Vesole, D. H., Callander, N. S., Fonseca, R., Williams, M. E., … Siegel, D. S. (2016). Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer Journal, 6(9), e466. https://doi.org/10.1038/bcj.2016.682044-5385https://hdl.handle.net/1805/11639In Eastern Cooperative Oncology Group-ACRIN E4A03, on completion of four cycles of therapy, newly diagnosed multiple myeloma patients had the option of proceeding to autologous peripheral blood stem cell transplant (ASCT) or continuing on their assigned therapy lenalidomide plus low-dose dexamethasone (Ld) or lenalidomide plus high-dose dexamethasone (LD). This landmark analysis compared the outcome of 431 patients surviving their first four cycles of therapy pursuing early ASCT to those continuing on their assigned therapy. Survival distributions were estimated using the Kaplan–Meier method and compared with log-rank test. Ninety patients (21%) opted for early ASCT. The 1-, 2-, 3-, 4- anden-USAttribution 4.0 InternationalOncologyStem CellsTransplantsArticle